MR001 is named as an intervention in 2 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is Shenzhen Majory Biotechnology Co., Ltd (1). The most-studied condition is Pancreatic Ductal Adenocarcinoma (PDAC).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy
NCT07235202 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1/2 | Recruiting | Shenzhen Majory Biotechnology Co., Ltd | China |
|
First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors
NCT06134531 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
|
Phase 1 | Not yet open | Nanfang Hospital, Southern Medical University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Shenzhen Majory Biotechnology Co., Ltd | 1 |
| Nanfang Hospital, Southern Medical University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name MR001 as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Shenzhen Majory Biotechnology Co., Ltd (1) and Nanfang Hospital, Southern Medical University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how MR001 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how MR001 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists MR001 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.